SpringWorks Therapeutics
SpringWorks Therapeutics Logo
About SpringWorks Therapeutics
SpringWorks Therapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations with rare diseases and cancer. Its lead products include OGSIVEO (nirogacestat), an oral gamma secretase inhibitor for desmoid tumors, and GOMEKLI (mirdametinib), a MEK1/2 inhibitor for neurofibromatosis type 1-associated plexiform neurofibromas. The company is also advancing therapies for ovarian granulosa cell tumors, low-grade gliomas, and other solid tumors, and is developing Brimarafenib (BGB-3245) for cancers with BRAF mutations. SpringWorks collaborates with industry and academic partners to advance targeted oncology therapies.
Address
100 Washington Boulevard,
Stamford, 06902
United States
Year founded
2019
Number of employees
300-400
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
